Compare Gemini Space Station Inc (GEMI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs Tango Therapeutics Inc. — how do they compare? Gemini Space Station Inc trades at $3.84 (market cap $531.57M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 7.1× Gemini Space Station Inc's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gemini Space Station Inc for 15 Days and Tango Therapeutics Inc. for 0 Days on average.
| GEMI | TNGX | |
|---|---|---|
Market Cap | $531.57M | $3.75B |
Volume | 1,676,380 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $22.36 | $32.90 |
52-Week Low | $3.54 | $7.50 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $510.60M | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.10, down 0.24% with bearish technical signals despite recent price surges. The company reported Q2 2026 revenue growth of 37% year-over-year but missed earnings estimates with a net loss of -$517 million. Analyst consensus shows mixed sentiment with a $5.25 price target, while technical indicators show oversold conditions with RSI at 10.68.
The stock faces significant fundamental challenges with negative profit margins and cash burn, though revenue diversification shows promise. Near-term catalysts include SEC regulatory developments for tokenized stocks, but legal risks and persistent losses create substantial downside potential for investors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
